Accommodating structurally diverse peptides in proteins  by Wilkinson, Anthony J.
Minireview 519 
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Many peptide-binding proteins must bind numerous 
ligands that differ in size, sequence and sometimes 
orientation. A variety of strategies for coping with 
structurally diVeKe peptide ligands have been revealed 
by biochemical and structural studies of proteins with 
roles in immunity, transport and signal transduction. 
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Peptides are widespread in nature and serve a variety of 
functions acting, for example, as a source of nutrients for 
microorganisms, as cell-signalling molecules, as recogni- 
tion elements for the immune system and, of course, as 
segments of proteins. The interactions of peptides with 
their receptor proteins are central to the molecular biology 
of the cell and research in this area is consequently flour- 
ishing (reviewed in [l-3]). Generally the binding is 
sequence specific, but some proteins must tolerate 
peptide ligands that are structurally and chemically 
diverse. Different proteins have evolved different solu- 
tions to the problem of how to bind peptides efficiently 
without absolute sequence specificity. The varied nature 
of the protein-peptide interactions that give rise to this 
sequence tolerance is illustrated here by four examples: 
the major histocompatibility complex (MHC) molecules 
that display peptides as part of immune surveillance, the 
bacterial oligopeptide transporter protein OppA, and two 
peptide-binding molecules involved in signal transduction 
(calmodulin and SH3 domains). 
MHC: sidechain podcets and the importance of ends 
As part of a complex mechanism for combating intracellu- 
lar pathogens such as viruses and mycobacteria, protea- 
somes in eukaryotic cells perpetually digest a proportion 
of the proteins in the cytosol, producing peptide frag- 
ments that are subsequently transported into the endo- 
plasmic reticulum. Here, the peptides form complexes 
with class I MHC proteins. These complexes are then 
transported to the cell surface, where the membrane-asso- 
ciated MHC molecules display the bound peptides to the 
outside world. The peptides presented in this way are a 
representative sampling of the cellular environment; most 
will have originated from normal cellular ‘self’ proteins, 
but occasionally a cell will display ‘foreign’ peptides, pro- 
viding a signal that it contains abnormal proteins, for 
instance those of an infecting virus. The class I MHC 
complexes are scrutinized by T-cell receptors (TCRs). 
These cell-surface receptors, like the immunoglobulins, 
have hypervariable antigen-recognition sequences. The 
recognition of a foreign peptide in complex with a class I 
MHC protein by TCRs on cytotoxic T cells leads to the 
activation of these cells and destruction of the infected 
cells. The activation of helper T cells, which coordinate 
other aspects of the immune response, is similar in princi- 
ple, but in this case the TCRs recognize peptides derived 
from proteins taken up by endocytosis and displayed on 
class II MHC proteins. 
Immune responses to the enormous array of potential 
pathogens rely on the capacity of the MHC proteins to 
bind peptides very tightly (Kd < 10e9 M) but with low 
specificity. Although MHC proteins are quite variable in 
sequence (polymorphic) within a population, an indivi- 
dual expresses only a handful of MHC proteins of each 
class; to ensure that peptides can be presented from a 
vast array of potential pathogens, each MHC protein 
must be able to bind a huge number of peptides. Crystal 
structures of the MHC proteins show very clearly how 
this is achieved [4]. 
Class I and class II MHC proteins are closely related in 
structure. Each class of protein contains a peptide-binding 
groove whose floor is formed by an eight-stranded P-sheet 
(on a platform formed by a pair of immunoglobulin-like 
domains) and whose sides are formed by a concave 
arrangement of a-helices (Fig. 1). Polymorphic residues 
cluster in the peptide binding site, so that different MHC 
proteins bind to different subsets of available peptides. 
For class I MHC proteins, the preferred peptides are 8 to 
11 amino acid residues long. In the complexes, the 
peptide is generally found in an extended conformation 
with the main-chain atoms of the amino- and carboxy- 
terminal residues interacting directly and extensively with 
the protein. In particular, the peptide’s a-NH3+ and 
rx-COO- groups are buried and form interactions which 
contribute much of the overall binding energy. 
Although MHC proteins can bind to a wide range of pep- 
tides, they are not completely non-selective. At some 
peptide positions there is a wide tolerance of different 
sidechains, but at a few positions the sidechains are 
buried in pockets which have strong preferences for resi- 
dues of a given type. This restricts the range of peptides 
that can be bound to those possessing the necessary 
‘motif’. For example, one human class I MHC allotype, 
HLA-AZ, prefers peptides with large aliphatic sidechains 
at residue-2 (PZ) and small hydrophobic sidechains at the 
carboxy-terminal position, while in another, HLA-Aw68, 
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Figure 1 
Peptides bind to MHC proteins in a peptide- 
binding groove that is partially exposed to 
solvent. Stereoview of a peptide complex of 
the class I MHC protein HlA-AP. The protein 
is represented as a yellow ribbon with the 
o-helical segments that frame the ligand 
coloured in blue. The peptide ligand is a 
nonamer (Thr-Leu-Thr-Ser-Cys-Asn-Thr-Ser- 
Val) derived from the envelope glycoprotein 
gpl20 (residues 195-207) of human 
immunodeficiency virus (HIV), and is 
represented in red. The coordinates are from 
the Brookhaven Data Bank, file 1 hhg.pdb [5]. 
the side chains at the corresponding positions are bound 
in cavities which are specific for valinelthreonine and 
lysine/arginine respectively [5,6]. In the mouse class I 
MHC molecule H-2Kb the arrangement of specificity 
pockets is different and the sidechains of residues at 
positions 2 and 5 pack together in a shared binding 
pocket giving rise to preferred pairings of sidechains at 
these positions [7]. The interactions made by the 
peptide termini with class I MHC molecules are usually 
maintained in complexes with peptides of differing 
lengths. As a result, the central residues of peptides 
longer than nonamers bulge out from the protein [6]. 
These central residues exhibit the most variety in struc- 
ture and conformation, and are among the most accessible 
for interactions with the TCR. 
Class II MHC proteins have a very similar structure to the 
class I MHC proteins, with the notable difference that 
the peptide binding groove is open at both ends. Class II 
MHC proteins can thus bind peptides of arbitrary length, 
but, unlike class I MHC proteins, do not take advantage 
of the binding energy available from burying the a-NH3+ 
and a-COO- groups at each end of the peptide. Peptides 
bound to HLA-DRl (a human class II MHC allele) 
assume a polyproline type II helical conformation over 
much of the length of the 13 residues that reside in the 
binding site [8]. Three asparagine sidechains from the 
protein, each of which forms bidentate hydrogen bonds 
with main-chain C=O and N-H groups in adjacent 
peptide bonds of the ligand, appear to be important in 
determining the peptide conformation. In this arrange- 
ment, the ligand sidechains that are solvent exposed and 
the ligand sidechains that are buried in the protein are 
each regularly spaced along the length of the peptide. 
OppA - a Venus flytrap 
The oligopeptide transporter protein OppA must also 
bind peptides of diverse sequence, the more diverse the 
better. OppA is the initial receptor protein for, and 
defines the specificity of, the bacterial oligopeptide per- 
mease, which transports extracellular peptides to the 
cytoplasm. It is an abundant, soluble protein that cap- 
tures peptides in the periplasm and delivers them to a 
complex of two membrane-spanning proteins (OppB and 
OppC), which form a channel through which the solute 
passes. Two cytoplasmic membrane-associated proteins 
(OppD and OppF) are responsible for coupling ATP 
hydrolysis to peptide transport. Although genetic studies 
indicate that the oligopeptide permease can transport 
peptides of two to five amino acid residues regardless of 
sequence, binding studies suggest that OppA has highest 
affinity for tripeptides and tetrapeptides (with a K, of 
- 10e6 M). Dipeptides are transported predominantly by 
the closely related dipeptide permease, which has its 
own set of membrane components, and periplasmic 
binding protein (DppA). 
The crystal structures of OppA and DppA reveal that 
their ligands are completely sequestered from bulk 
solvent and enclosed in the protein interior; the mecha- 
nism of binding has been likened to that of a Venus fly- 
trap (Fig. 2; [9-121). Such complete enclosure of ligands is 
a feature of the periplasmic substrate binding proteins, 
and is usually associated with complementary interactions 
and therefore with specificity. Indeed, the binding 
proteins associated with sugar and anion transporters 
are often exquisitely selective [13]. Complete removal of 
the ligand from bulk solvent in this way is presumably a 
prerequisite for specific transmembrane transport. 
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Figure 2 
OppA completely surrounds its ligand, but 
makes few contacts with the peptide 
sidechains. Stereoview of the crystal 
structure of OppA, drawn as a yellow ribbon 
with cu-helices in blue, in complex with the 
tetrapeptide Lys-Lys-Lys-Ala which is 
represented as red van der Waals spheres 
[lo]. The coordinates are from the 
Brookhaven Data Bank, file 1 olc.pdb. 
The peptide in OppA is bound in an extended conforma- 
tion so that the charged ligand termini and its polar main- 
chain hydrogen-bonding groups, common to all peptides, 
are available to make interactions with the protein. A salt 
bridge is formed between the acidic sidechain of Asp419 
on the protein and the o-amino group of the peptide 
ligand, and there are extensive B-sheet-like interactions 
between main-chain hydrogen-bonding groups on the 
peptide and corresponding groups on the protein. Pep- 
tides of different length are accommodated not by bulging 
of the peptide as is seen for class I MHC, nor by extension 
out of the binding site as seen for class II MHC. Instead, a 
series of positively charged sidechains is located along the 
binding cavity in such a way that the a-carboxylate groups 
of peptide ligands of different lengths form ion pairs with 
different protein sidechains. 
The sidechains of the peptide ligands, which can differ in 
size, shape, polarity and charge, project into spacious 
hydrated cavities. Few direct interactions are made 
between OppA and the ligand sidechains, presumably 
because such interactions would result in discrimination. 
Buried water molecules are important in adapting the 
pocket to accommodate the different ligands; water mole- 
cules occupy the volume not taken up by the peptide 
sidechains, fulfil the hydrogen-bonding potential of the 
ligand sidechains and the surrounding protein residues, 
and solvate any charged groups. 
The different modes of peptide binding by MHC proteins 
and OppA are dictated by the receptors with which the 
complexes interact. MHC-peptide complexes are sur- 
veyed by a population of T cells, each with a different 
TCR, and the role of MHC is to advertise the peptides so 
that differences of sequence are readily apparent. This 
allows specific interactions to be made with those TCRs 
bearing complementary surfaces leading to directed 
immune responses. In marked contrast, OppA has a single 
receptor made up of the membrane components of its 
transport system. Efficient transport requires that this 
receptor be able to distinguish the unliganded from the 
liganded form of OppA, but interact with the liganded 
form of OppA regardless of the sequence of the bound 
peptide. A Venus fly-trap mechanism of ligand binding 
achieves this by masking differences among peptide 
sequences and by creating a protein surface that is unique 
to the liganded form. 
Calmodulin: peptide wrapping 
Permissive peptide binding is also observed in calmod- 
ulin (CaM), a calcium-binding protein that has a pivotal 
regulatory role in cellular metabolism. Calcium is a major 
intracellular signalling molecule in eukaryotic cells, its 
concentration transiently rising steeply and falling in 
response to extracellular stimuli. CaM is a subunit of a 
number of calcium-regulated enzymes, including protein 
kinases, protein phosphatases, cyclic nucleotide phos- 
phodiesterases and nitric oxide synthetase, which them- 
selves serve regulatory functions. The crystal structure of 
calcium-CaM reveals a bilobate molecule. Each lobe 
contains two calcium ions, each of which is bound in a 
helix-loop-helix motif that is referred to as an EF-hand 
(Fig. 3a). The two lobes are joined by a connecting 
segment of o-helix giving rise to an overall dumbbell- 
shaped molecule. 
The interactions of CaM with its target enzymes are not 
understood in detail, although the CaM-binding regions 
within a number of these molecules have been narrowed 
down to -20-residue segments of polypeptide. Synthetic 
peptides corresponding to these segments bind to 
calmodulin with affmities approaching those of the intact 
target proteins (Kd -1 nM) implying that the major CaM- 
binding determinants reside in these short contiguous 
sequences. The paucity of sequence similarity among 
these peptides is striking, and it seems that CaM has low 
sequence specificity. Indeed, other studies have shown 
that CaM can bind a wide range of synthetic as well as 
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Figure 3 
Calmodulin bends to wrap around a peptide 
ligand. The crystal structures of (a) 
calmodulin and (b) calmodulin in complex 
with a peptide (stereoview) are shown to 
illustrate the dramatic change in conformation 
that accompanies peptide binding [I 51. The 
protein backbone is shown as a ribbon 
(yellow) with the a-helical regions highlighted 
in blue. The four calcium ions, two in each 
lobe, are represented as green spheres. In 
(a), the amino-terminal lobe is at the top. In 
(b), the 20-residue peptide (red) derived from 
smooth muscle myosin light chain kinase 
assumes an a-helical conformation with its 
amino terminus on the left. The view is such 
that the orientation of the amino-terminal lobe 
of the protein (right) is similar to that in (a). 
The coordinates are from the Brookhaven 
Data Bank, files 1 cll.pdb and 1 cdl.pdb. 
natural peptides, including peptides composed of D-amino 
acids. These peptides share no obvious sequence similar- 
ity other than a high propensity for a-helix formation and 
a predominance of basic over acidic residues. 
The three-dimensional structures of CaM-peptide com- 
plexes confirm that peptide ligands are bound in an 
a-helical conformation, and reveal a dramatic reorganiza- 
tion of the calmodulin domains. The o-helix connecting 
the two CaM lobes unravels to form two shorter a-helices 
connected by a short segment of coil. This unravelling 
allows relative movement of the two lobes so that they 
wrap around and substantially bury the peptide ligand in a 
manner that has been likened to two hands grasping a rope 
[14] (Fig. 3b). Different peptides can be accommodated 
through the capacity of the connecting helix to act as a vari- 
able ‘expansion joint’ that can be unravelled to varying 
extents, so allowing subtly different relative arrangements 
of the lobes according to ligand sequence [15]. The 
peptide-binding tunnel that results has a hydrophobic 
centre containing a number of apolar pockets, while its 
extremities feature acidic residues [ 161. Modelling studies 
based on CaM-ligand structures led to the proposal that 
ideal calmodulin-binding peptides should contain a set of 
bulky aliphatic or aromatic sidechains to fill the apolar cavi- 
ties, with flanking basic sidechains to give electrostatic 
interactions with the acidic residues on CaM [17]. 
However, analysis of a series of peptides derived from the 
CaM-recognition sequence of skeletal muscle myosin light 
chain kinase (sMLCK), corresponding to single point 
mutations of each residue to alanine, suggests that no 
single amino-acid residue is essential for tight binding [18]. 
Each of the alanine variants binds to CaM with greater 
affmity than the sMLCK peptide, emphasizing again the 
catholic character of the binding site and the difficulties in 
defining a CaM-binding motif. 
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The o-helical conformation of the peptide ligand provides 
no opportunity for CaM to form tight, specific interactions 
with the peptide backbone, as seen in OppA and the 
MHC complexes. Instead, CaM achieves high affinity 
binding by making extensive interactions with the 
sidechains on its peptide ligands. This is remarkable in 
view of its low sequence specificity. A further fascinating 
and unanswered question concerns how calmodulin grasps 
its physiological ligands, which are not free peptides but 
segments of a folded polypeptide that is usually part of a 
large enzyme assembly. 
SH3 domains: backwards binding 
SH3 domains are also versatile in the organization of their 
complexes with peptides, although they are the most 
sequence-selective of the examples discussed here. SH, or 
Src-homology, domains are widespread in proteins 
involved in the transmission of signals from receptor 
protein-tyrosine kinases, and were initially discovered in 
cytoplasmic protein-tyrosine kinases related to c-Src, 
hence the name. They mediate protein-protein interac- 
tions among the components of the complex molecular 
circuitry that forms the signal transduction pathways of 
eukaryotic cells [19,20]. SH3 domains are composed of 
-60 amino acid residues folded to form a pair of P-sheets 
that pack together in a barrel-like arrangement (Fig. 4). 
The amino- and carboxyl-termini are close together in 
space, consistent with the idea that these domains are 
independent folding units or modules that can be inserted 
at different locations within a protein. SH3 domains bind 
to short proline-rich sequences in their target proteins and 
in related synthetic peptides. 
In the complexes, the peptides form a left-handed polypro- 
line type II helix. This conformation results from the 
regular arrangement of prolines in the peptide, not from 
restrictions imposed by the binding surface (unlike the 
case of HLA-DRl-peptide complexes). The curious 
feature of SH3 domains is that, depending on the 
sequences that flank the proline-rich motif, the amino to 
carboxyl orientation of the ligand with respect to the 
Figure 4 
protein can be reversed [21,22]. This is most vividly illus- 
trated for the SH3 domain of Src, for which NMR struc- 
tures of complexes with peptides bound in both 
orientations have been determined. Protein sidechains 
form hydrogen bonds with three main-chain carbonyl 
oxygens on the ligand, while three shallow pockets in the 
SH3 domain accommodate the sidechains of five peptide 
residues. The first two pockets each bind a proline 
sidechain and the sidechain of an adjacent, usually 
hydrophobic, residue. Due to pseudo-symmetry inherent 
in the polyproline type II helix, these interactions of the 
SH3 domain with the main-chain and sidechain groups on 
the ligand are largely preserved when the peptide binds in 
the opposite orientation. The third pocket binds an argi- 
nine sidechain, which forms an ion pair with a conserved 
acidic residue in the SH3 domain. It is the amino-terminal 
or carboxy-terminal location of this arginine with respect to 
the proline-rich motif that determines the orientation in 
which the peptide binds. Interestingly, in the crystal struc- 
ture of the SH3 domain from phosphatidylinositol3-kinase 
(PI3K), the three ligand-binding pockets are occupied by 
amino-acid residues from two different symmetry-related 
protein molecules [23]. The interactions of these 
sidechains with the SH3 domain are similar to those seen 
in the complexes with synthetic PI3K peptide ligands, 
though the main-chain conformation is clearly different. 
Although the peptide-complex structures provide models 
for how SH3 domains engage their intracellular ligands, 
structures of much larger complexes including SH3 
domains and their target proteins are needed to illuminate 
the molecular mechanics of signal transduction properly. 
Diverse routes to diversity 
The studies of peptide complexes summarized above 
show that proteins can use a variety of strategies to bind 
peptides without imposing rigid sequence selectivity. 
Diversity in sequence recognition is most easily achieved 
by avoiding contact with some or all of the ligand 
sidechains; these sidechains can be exposed to the 
solvent, as seen for MHC complexes, or may be enclosed 
within a versatile ligand-binding envelope, as in OppA. A 
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second source of diversity is structural malleability, either 
in the protein, as seen in calmodulin, or in the peptide, as 
with the bulging observed in complexes of class I MHC 
proteins with longer peptides. For the SH3 domains, the 
symmetry of the ligand’s polyproline type II helix and the 
use of relatively non-specific hydrophobic sidechain 
binding pockets lead to a rather curious orientational 
ambivalence in peptide binding by these proteins. 
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